The goal of this clinical research study is to find the highest tolerable dose of Avastin (bevacizumab) and Torisel (temsirolimus) that can be given in combination with either valproic acid or cetuximab to patients with advanced cancer that is refractory. The safety of this drug combination will also be studied.
Bevacizumab is designed to block the growth of blood vessels, which may help to slow or block the growth of cancer.
Temsirolimus is designed to block the growth of cancer cells, which may cause cancer cells to die.
Valproic acid is an anti-seizure drug that may be able to activate tumor-fighting genes, causing cancer cells to die.
Cetuximab is designed to block a certain protein, called EGFR, that is thought to cause cancer cells to grow. This may cause cancer cells to die.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.